Your browser doesn't support javascript.
loading
Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial.
Delahunt, B; Steigler, A; Atkinson, C; Christie, D; Duchesne, G; Egevad, L; Joseph, D; Kenwright, D N; Matthews, J; Murray, J D; Oldmeadow, C; Samaratunga, H; Spry, N A; Thunders, M C; Hondermarck, H; Denham, J W.
Afiliação
  • Delahunt B; Department of Pathology and Molecular Medicine and Health Sciences, University of Otago, and Southern Community Laboratory, Wellington, New Zealand. Electronic address: brett.delahunt@otago.ac.nz.
  • Steigler A; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
  • Atkinson C; St Georges Cancer Care Centre, Christchurch, New Zealand.
  • Christie D; Genesis Care, Tugun, Qld, Australia.
  • Duchesne G; Peter MacCallum Cancer Centre and University of Melbourne, Vic, Australia.
  • Egevad L; Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden.
  • Joseph D; Sir Charles Gairdner Hospital, Perth, WA, Australia.
  • Kenwright DN; Department of Pathology and Molecular Medicine and Health Sciences, University of Otago, and Southern Community Laboratory, Wellington, New Zealand.
  • Matthews J; Auckland City Hospital, Auckland, New Zealand.
  • Murray JD; Department of Pathology and Molecular Medicine and Health Sciences, University of Otago, and Southern Community Laboratory, Wellington, New Zealand.
  • Oldmeadow C; Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Samaratunga H; Aquesta Uropathology and University of Queensland, Brisbane, Qld, Australia.
  • Spry NA; Genesis Care, Perth, WA, Australia.
  • Thunders MC; Department of Pathology and Molecular Medicine and Health Sciences, University of Otago, and Southern Community Laboratory, Wellington, New Zealand.
  • Hondermarck H; Hunter Medical Research Institute, Newcastle, NSW, Australia; School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW, Australia.
  • Denham JW; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
Pathology ; 54(1): 49-54, 2022 Feb.
Article em En | MEDLINE | ID: mdl-34955242
ABSTRACT
Previous reports have shown that quantification of high tumour grade is of prognostic significance for patients with prostate cancer. In particular, percent Gleason pattern 4 (GP4) has been shown to predict outcome in several studies, although conflicting results have also been reported. A major issue with these studies is that they rely on surrogate markers of outcome rather than patient survival. We have investigated the prognostic predictive value of quantifying GP4 in a series of prostatic biopsies containing Gleason score 3+4=7 and 4+3=7 tumours. It was found that the length of GP4 tumour determined from the measurement of all biopsy cores from a single patient, percent GP4 present and absolute GP4 were all significantly associated with distant progression of tumour, all-cause mortality and cancer-specific mortality over a 10-year follow-up period. Assessment of the relative prognostic significance showed that these parameters outperformed division of cases according to Gleason score (3+4=7 versus 4+3=7). International Society of Urological Pathology (ISUP) Grade Groups currently divide these tumours, according to Gleason grading guidelines, into grade 2 (3+4=7) and grade 3 (4+3=7). Our results indicate that this simple classification results in the loss of important prognostic information. In view of this we would recommend that ISUP Grade Groups 2 and 3 be amalgamated as grade 2 tumour with the percentage of GP4 carcinoma being appended to the final grade, e.g., 3+4=7 carcinoma with 40% pattern 4 tumour would be classified as ISUP Grade Group 2 (40%).
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Prognóstico / Neoplasias da Próstata / Adenocarcinoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Pathology Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Prognóstico / Neoplasias da Próstata / Adenocarcinoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Pathology Ano de publicação: 2022 Tipo de documento: Article